Аннотация
Явления гиперактивности мочевого пузыря встречаются часто. Гиперактивный мочевой пузырь (ГАМП) требует безусловной коррекции, так как существенно снижает качество жизни пациента. Проведенный литературный обзор установил, что фармакокинетика и особенности метаболизма троспия хлорида делают его предпочтительным у пожилых и коморбидных больных. Прослеживается четкая взаимосвязь между дисфункцией кишечника и мочевого пузыря. Обнаруженные экспериментально свойства ребамипида – восстанавливать структуру и функцию поврежденного уротелия, а также подавлять явления гиперактивности мочевого пузыря, требуют дальнейшего пристального изучения и внедрения этого препарата в клиническую практику лечения больных хроническим циститом и ГАМП.
Ключевые слова: мочевой пузырь, кишечник, гиперактивный мочевой пузырь, синдром повышенной проницаемости, троспия хлорид, ребамипид.
Ключевые слова: мочевой пузырь, кишечник, гиперактивный мочевой пузырь, синдром повышенной проницаемости, троспия хлорид, ребамипид.
Об авторе
Е.В. Кульчавеня
ФГБУ «Новосибирский научно-исследовательский институт туберкулеза» Минздрава России, Новосибирск, Россия;
ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск, Россия
urotub@yandex.ru
Список литературы
1. Казилов Ю.Б., Гаджиева З.К. Распространенность различных нарушений мочеиспускания. Урология. 2016; 5: 109–14.
[Kazilov Yu.B., Gadzhieva Z.K. Rasprostranennost' razlichnykh narushenii mocheispuskaniia. Urologiia. 2016; 5: 109–14 (in Russian).]
2. Кульчавеня Е.В., Холтобин Д.П., Шевченко С.Ю. и др. Частота хронического простатита в структуре амбулаторного урологического приема. Экспериментальная и клиническая урология. 2015; 1: 16–9.
[Kul'chavenia E.V., Kholtobin D.P., Shevchenko S.Iu. et al. Chastota khronicheskogo prostatita v strukture ambulatornogo urologicheskogo priema. Eksperimental'naia i klinicheskaia urologiia. 2015; 1:
16–9 (in Russian).]
3. Harnett MD, Shipley J, MacLean L et al. Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects. Clin Drug Investig 2013; 33 (2): 133–41. DOI: 10.1007/s40261-012-0039-8
4. Yu HJ, Liu CY, Lee KL et al. Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking. Urol Int 2006; 77: 327–33. DOI: 10.1111/j.1464-410X.2009.08371.x
5. Hsu FC, Weeks CE, Selph SS et al. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J 2019; 30 (10): 1603–17. DOI: 10.1007/s00192-019-04022-8
6. Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology 2012; 79 (1): 95–101. DOI: 10.1016/j.urology.2011.09.010
7. Лучинский С.А. Фармакологическая коррекция сексуальных дисфункций у женщин с гиперактивным мочевым пузырем. Автореф. дис. ... канд. мед. наук. Тихоокеан. гос. мед. университет. Владивосток, 2015.
[Luchinskii S.A. Farmakologicheskaia korrektsiia seksual'nykh disfunktsii u zhenshchin s giperaktivnym mochevym puzyrem. Avtoref. dis. ... kand. med. nauk. Tikhookean. gos. med. universitet. Vladivostok, 2015 (in Russian).]
8. Coyne KS, Sexton CC, Irwin DE et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101 (11): 1388–95. DOI: 10.1111/j.1464-410X.2008.07601.x
9. Coyne KS, Wein AJ, Tubaro A et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 (Suppl. 3): 4–11.
10. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20 (6): 327–6. DOI: 10.1007/s00345-002-0301-4
11. Sexton CC, Coyne KS, Vats V et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am
J Manag Care 2009; 15 (Suppl. 4): S98–s107.
12. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2002; 55 (Suppl.): 33–46.
13. Hsiao SM, Chang TC, Chen CH et al. Frequent nocturia episodes, a suboptimal response to treatment, and small bladder capacity predict the need for persistent antimuscarinic therapy or re-treatment after discontinuation of antimuscarinics in female overactive bladder. Menopause 2017; 24: 100–4.
14. Hsiao SM, Liao SC, Chen CH et al. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects. Maturitas 2014; 79: 428–34.
15. Hsiao SM, Lin HH, Kuo HC. The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J 2012; 23: 935–40.
16. Kuo HC, Lee KS, Na Y et al. Results of a randomized, double-blind, parallel-group, placebo and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn 2015; 34: 685–92.
17. Abrams P, Andersson KE, Buccafusco JJ et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006; 148 (5): 565–78. DOI: 10.1038/sj.bjp.0706780
18. Kumar V, Templeman L, Chapple CR, Chess-Williams R. Recent developments in the management of detrusor overactivity. Curr Opin Urol 2003; 13 (4): 285–91.
19. Manjunatha R, Pundarikaksha HP, Hanumantharaju BK, Anusha SJ. A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder.
J Clin Diagn Res 2015; 9 (3): FC05–9.
20. Biastre K, Burnakis T. Trospium chloride treatment of overactive bladder. Ann Pharmacother 2009; 43 (2): 283–95. DOI: 10.1345/aph.1L160
21. Кульчавеня Е.В. Новый подход к пониманию патогенеза и к лечению инфекционно-воспалительных заболеваний мочеполовой системы. Урология. 2020; 5: 99–105. DOI: 10.18565/urology. 2020.5.99-105
[Kul'chavenia E.V. Novyi podkhod k ponimaniiu patogeneza i k lecheniiu infektsionno-vospalitel'nykh zabolevanii mochepolovoi sistemy. Urologiia. 2020; 5: 99–105. DOI: 10.18565/urology.2020.5.99-105 (in Russian).]
22. Wolnicki M, Aleksandrovych V, Gil K. Interstitial cells of Cajal and telocytes in the urinary system: facts and distribution. Folia Med Cracov 2016; 56 (4): 81–9.
23. Faussone-Pellegrini MS, Cortesini C, Romagnoli P. Ultrastructure of the tunica muscularis of the cardial portion of the human esophagus and stomach, with special reference to the so-called Cajal’s interstitial cells. Arch Ital Anat Embriol 1977; 82: 157–77.
24. Huizinga JD, Zarate N, Farrugia G. Physiology, injury, and recovery of interstitial cells of Cajal: basic and clinical science. Gastroenterology 2009; 137: 1548–56.
25. Koh SD, Sanders KM, Ward SM. Spontaneous electrical rhythmicity in cultured interstitial cells of cajal from the murine small intestine.
J Physiol 1998; 513: 203–13.
26. Huizinga JD, Thuneberg L, Klüppel M et al. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347–9.
27. Farrugia G. Interstitial cells of Cajal in health and disease. Neurogastroenterol Motil 2008; 20 (Suppl/ 1): 54–63.
28. McCloskey K.D. Interstitial cells in the urinary bladder – localization and function. Neurourol Urodyn 2010; 29: 82–7.
29. Gil K, Urbanowicz W, Thor P. Localization and functions of c-kit positive cells in the urinary tract. Folia Med Cracov 2009; 50: 85–93.
30. Koleda P, Pilecki W. Nature of Interstitial Cells of Cajal of the Upper Urinary Tract. Advanc Clin Experiment Med 2014; 23 (4): 627–32.
31. Metzger R, Schuster T, Till H et al. Cajal-like cells in the upper urinary tract: comparative study in various species. Pediatr Surg Int 2005; 21 (3): 169–74.
32. Яцина А.И., Вернигородский С.В., Костев Ф.И. Морфологический анализ интерстициальных клеток кахаля и базофильных гранулоцитов при гиперактивном мочевом пузыре и стрессовом недержании мочи в эксперименте и при фармакокоррекции. Вестник морфологии. 2018; 24 (2): 5–13.
[Iatsina A.I., Vernigorodskii S.V., Kostev F.I. Morfologicheskii analiz interstitsial'nykh kletok kakhalia i bazofil'nykh granulotsitov pri giperaktivnom mochevom puzyre i stressovom nederzhanii mochi v eksperimente i pri farmakokorrektsii. Vestnik morfologii. 2018; 24 (2): 5–13 (in Russian).]
33. Chuang FC, Liu HT, Wang LY, Kuo HC. Overactive bladder changes with time: a 5-year longitudinal follow up of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels. J Urol 2014; 192: 458–63.
34. Chung SD, Liu HT, Lin H, Kuo HC. Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 2011; 30: 417–20.
35. Kupelian V, Rosen RC, Roehrborn CG et al. Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) survey. BJU Int 2012; 110: 401–7.
36. Kuo HC. Potential biomarkers utilized to define and manage overactive bladder syndrome. Low Urin Tract Symptoms 2012; 4 (Suppl. 1): 32–41.
37. Abreu GE, Dourado ER, Alves DN et al. Functional constipation and overactive bladder in women: a population-based study. Arq Gastroenterol 2018; 55 (Suppl. 1): 35–40. DOI: 10.1590/S0004-2803.201800000-46
38. Mugie SM, Koppen IJN, van den Berg MM et al. Brain processing of rectal sensation in adolescents with functional defecation disorders and healthy controls. Neurogastroenterol Motil 2018; 30:
e13228.
39. Mugie SM, Benninga MA, Di Lorenzo C. Epidemiology of constipation in children and adults: a systematic review. Best Pract Res Clin Gastroenterol 2011; 25: 3–18.
40. Wiley JW, Chang L. Functional Bowel Disorders. Gastroenterology 2018; 155 (1): 1–4. DOI: 10.1053/j.gastro.2018.02.014
41. Sampaio C, Sousa AS, Fraga LG et al. Constipation and lower urinary tract dysfunction in children and adolescents: a population-based study. Front Pediatr 2016; 4: 101.
42. Coyne KS, Cash B, Kopp Z et al. The prevalence of chronic constipation and faecal incontinence among men and women with symptoms of overactive bladder. BJU Int 2011; 107: 254–61.
43. Maeda T, Tomita M, Nakazawa A et al. Female functional constipation is associated with overactive bladder symptoms and urinary incontinence. Biomed Res Int 2017; 2017: 2138073.
44. Behzad E, Pirzadeh S, Mohseni M. Bowel habit reference values and abnormalities in young Iranian healthy adults. Dig Dis Sci 2007; 52: 1810–3.
45. Howell SC, Quine S, Talley NJ. Low social class is linked to upper gastrointestinal symptoms in an Australian sample of urban adults. Scand J Gastroenterol 2006; 41: 657–66.
46. Schmidt FM, Santos VL. Prevalence of constipation in the general adult population: an integrative review. Wound Ostomy Continence Nurs 2014; 41: 70–6.
47. Panayi DC, Khullar V, Digesu GA et al. Rectal distension: the effect on bladder function. Neurourol Urodyn 2011; 30: 344–7.
48. McMahon SB, Morrison JF. Two group of spinal interneurones that respond to stimulation of the abdominal viscera of the cat. J Physiol 1982; 322: 21–34.
49. Rouzade-Dominguez ML, Miselis R, Valentino RJ. Central representation of bladder and colon revealed by dual transsynaptic tracing in the rat: substrates for pelvic visceral coordination. Eur J Neurosci 2003; 18: 3311–24.
50. Ketai LH, Komesu YM, Dodd AB et al. Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol 2016; 215: 449.
51. Kato T, Honda Y, Kurita Y et al. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers. PLoS One 2017; 12 (4): e0175626. DOI: 10.1371/journal.pone.0175626
52. Manfredo Vieira S, Hiltensperger M, Kumar V et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans [published correction appears in Science 2018; 360 (6388)] Science 2018; 359 (6380): 1156–61. DOI: 10.1126/science.aar7201
53. Knoop KA, McDonald KG, Kulkarni DH, Newberry RD. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut 2016; 65 (7): 1100–9. DOI: 10.1136/gutjnl-2014-309059
54. De-Souza DA, Greene LJ. Intestinal permeability and systemic infections in critically ill patients: effect of glutamine. Crit Care Med 2005; 33 (5): 1125–35. DOI: 10.1097/01.ccm.0000162680.52397.97
55. Terpstra ML, Singh R, Geerlings SE, Bemelman FJ. Measurement of the intestinal permeability in chronic kidney disease.World J Nephrol 2016; 5 (4): 378–88. DOI: 10.5527/wjn.v5.i4.378
56. Fry CH, Vahabi B. The Role of the Mucosa in Normal and Abnormal Bladder Function. Basic Clin Pharmacol Toxicol 2016; 119 (Suppl. 3): 57–62. DOI:10.1111/bcpt.12626
57. Кунст М.А., Якупова С.П., Зинкевич О.Д. и др. Роль микробной инфекции и проницаемости кишечника в патогенезе ревматоидного артрита. Практическая медицина. 2014; 4 (80): 56–8.
[Kunst M.A., Yakupova S.P., Zinkevich O.D. et al. The role of microbial infection and intestinal permeability in the pathogenesis of rheumatoid arthritis. Practical medicine. 2014; 4 (80): 56–8 (in Russian).]
58. Lee SJ. Recent advances in managing lower urinary tract infections. F1000Res 2018; 7: F1000 Faculty Rev-1964. DOI:10.12688/f1000research.16245.1
59. Tassopoulos A, Chalkias A, Papalois A et al. The effect of antioxidant supplementation on bacterial translocation after intestinal ischemia and reperfusion. Redox Rep 2017; 22 (1): 1–9. DOI: 10.1080/13510002.2016.1229893
60. Chin HJ, Oh YK, Jung YC et al. The phase II clinical study of rebamipide (mucosta tablet) on chronic glomerulonephritis patients. J Korean Society Clin Pharmacol Therapeut 1997; 5 (2), 170–82.
61. Sun M, Deng Z, Shi F et al. Rebamipide-loaded chitosan nanoparticles accelerate prostatic wound healing by inhibiting M1 macrophage-mediated inflammation via the NF-κB signaling pathway. Biomater Sci 2020; 8 (3): 912–25. DOI: 10.1039/c9bm01512d
62. Funahashi Y, Yoshida M, Yamamoto T et al. Intravesical application of rebamipide suppresses bladder inflammation in a rat cystitis model. J Urol 2014; 191 (4): 1147–52. DOI: 10.1016/j.juro.2013.11.026
63. Funahashi Y, Yoshida M, Yamamoto T et al. Intravesical application of rebamipide promotes urothelial healing in a rat cystitis model.
J Urol 2014; 192 (6): 1864–70. DOI: 10.1016/j.juro.2014.06.081
Для цитирования:Кульчавеня Е.В. Мочевой пузырь и кишечник – друзья или враги? Клинический разбор в общей медицине. 2020; 3: 39–44. DOI: 10.47407/kr2020.1.3.00022
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)